Article history: Received 15 June 2019 Revised 9 July 2019 Accepted 15 July 2019 Available online xxxx Introduction: Though seizures are a common complication after stroke, only little scientific evidence is available about the impact of epilepsy on cognitive functioning and quality of life in patients who have had a stroke. Therefore, we assessed these items in a case-control study. Methods: We studied 36 patients with poststroke epilepsy (PSE) and 36 matched patients who have had a stroke without epilepsy using parts of the FePsy (the computerized visual searching task (CVST) for central information processing speed and a reaction time test), the mini-mental-state examination (MMSE), the EuroQol, the strokeadapted Sickness Impact Profile questionnaire (SA-SIP-30), the Barthel index, the modified Rankin scale, and the National Institutes of Health stroke scale (NIHSS). Results: Patients with PSE had significantly lower scores on the CVST and MMSE. Generic quality of life was the same in patients with poststroke epilepsy and patients with stroke only, however, the SA-SIP-30 showed a lower disease-specific quality of life in patients with poststroke epilepsy. The Barthel index showed no difference between both groups, but both the modified Rankin scale and the NIHSS were significantly higher in patients with poststroke epilepsy, indicating more disability and neurological impairment in patients with PSE. Conclusions: We found that PSE relates to impaired cognitive functioning, a lower disease-specific quality of life and more disability and neurological impairment. This underlines the importance of further clinical research in this field.
Introduction
Seizures are a common complication after stroke [1, 2] , and although 25-50% of new-onset seizures in adults and elderly is caused by cerebrovascular disease [1, 3] , only little evidence is available about the impact of seizures and epilepsy on cognitive functioning and quality of life (QOL) in patients who have had a stroke. Winter et al. [4] showed in a cohort of 374 patients who have had a stroke, including 23 patients (6.1%) with poststroke epilepsy (PSE), that health-related QOL was significantly lower in patients with PSE. However, in this study, patients with PSE were compared with the complete population of patients who have had a stroke, including patients with less severe and smaller strokes, which might have introduced bias. Furthermore, there are no data on cognitive functioning in this cohort. We therefore performed a case-control study on cognitive functioning and QOL in patients with PSE matched to patients who have had a stroke with similar strokes without PSE. As cognitive function and QOL may be influenced by mood, level of disability, and neurological impairment, we also gathered information on these items.
Material and methods
We performed a case-control study in patients who have had a stroke with and without PSE treated at the Maastricht University Medical Center+ (MUMC+) in Maastricht, the Netherlands. Patients with PSE were identified by using a list of diagnosis codes from the hospital administration and searching for the combination of stroke and epilepsy in this list. Also, during the study period, all neurologists working at the MUMC+ informed the executive researcher (JVT) about patients with PSE they had under their care. Patients were contacted by phone to ask for participation in this study. All patients signed an informed consent before participation in this study. This study was approved by the medical ethical committee of the MUMC+.
We defined PSE clinically as the occurrence of one or more seizures, occurring more than one week after a stroke, which had to be confirmed by clinical symptoms with normal brain imaging or imaging showing a cerebral infarction or hemorrhage. Patients with a seizure and clear signs of cerebral infarction on imaging, although without clinical signs of stroke before their seizure, were also included. For inclusion, the diagnosis of PSE had to be at least 3 months old. We avoided possible effects of seizures on cognitive functioning by planning the test session at least 2 weeks after the last seizure.
We matched the patients who have had a stroke without epileptic seizures to the patients with PSE by age, sex, stroke type (lacunar stroke vs. cortical stroke vs. deep or lobar intracerebral hemorrhage (ICH)), lesion side, and time since stroke. When an exact match could not be found, we sought the best match concerning stroke type, lesion side, and time since stroke. The matching patients who have had a stroke without epileptic seizures were selected from the Maastricht Stroke Registry, an ongoing prospective register in which all consecutive patients presenting at the emergency department or outpatient clinic of the MUMC+ with a stroke are registered. We did not include patients (in neither group) with known severe cognitive deficits including global aphasia, as this would impede the adequate completion of the tests and questionnaires.
All patients eligible for this case-control study were invited to come to the outpatient clinic of the MUMC+ for a test session. Patients unable or unwilling to travel to the outpatient clinic were tested at home or at their care facility.
To assess cognitive function, we used two tests from the FePsy [5] , which is a test battery used for automated testing of cognitive functions in patients with epilepsy. We used the reaction time test (RT test), either auditory, in patients without hearing loss, or the visual RT test, as well as the computerized visual searching task (CVST), an information processing task. We started the test session with these two tests to avoid the influence of fatigue. In addition, we used the Dutch translation of the mini-mental-state examination (MMSE) as a cognitive function screening test [6] .
We measured QOL using a generic QOL scale, the EuroQol, and a stroke-specific QOL scale, the stroke-adapted Sickness Impact Profile (SA-SIP-30) questionnaire [7] [8] [9] . We screened for mood and anxiety disorders with the hospital anxiety and depression scale (HADS) [10] . We measured disability with the Barthel index [7] and the modified Rankin scale (mRS) [11] [12] [13] . To assess the severity of the stroke-related neurological impairment, we used the National Institutes of Health stroke scale (NIHSS) at time of the study, and retrospectively at time of the initial stroke [14] , when enough clinical information was available.
Statistical analysis
Descriptive statistics (mean, median, absolute numbers, and proportions) were calculated. T-tests, Mann-Whitney-U-tests, or Chi-square tests were used to compare groups with and without PSE, whichever was appropriate.
Results

Descriptive statistics
We included 36 patients with a clinical diagnosis of PSE and 36 age, sex, stroke type, lesion side, and time since stroke matched stroke only (SO) patients. Patient characteristics are shown in Table 1 .
Twenty nine patients with PSE used one antiepileptic drug (AED), five patients used two AEDs, and two patients did not use any AED. Antiepileptic drugs used are levetiracetam (16 pts), carbamazepine (11 pts), phenytoin (5 pts), valproate (4 pts), lamotrigine (1 pt), oxcarbazepine (1 pt), and pregabalin (1 pt). Two patients used the combination levetiracetam with carbamazepine, 1 patient valproate with levetiracetam, 1 patient valproate with carbamazepine, and 1 patient lamotrigine with carbamazepine.
Cognitive function
Three patients with PSE could fulfill neither the auditory nor the visual RT test, their results and the results of the matching patients with SO were excluded. This left 33 patients per group for the analyses. The RT in the group with PSE showed no statistically significant difference with the RT in the group with SO. For the CVST, four patients in the group with PSE were unable to complete the test and were therefore excluded, together with their matching patients with SO, leaving 32 pairs for the analyses. Two patients completed the test partially (10 and 11 items out of 20, respectively), their results were included in our analysis. Median response time for patients with PSE was 8.6 s, whereas for patients with SO the median response time was 7.1 s, which was significantly faster. The MMSE was refused by one patient in the group with PSE, leaving 35 pairs for the analyses. Mini-mental-state examination scores in the group with PSE were significantly lower than in the group with SO, which meant a worse cognitive function in the group with PSE (see Table 2 ).
Quality of life and mood
Patients with PSE showed a higher percentage of problems in 4 out of 5 dimensions of the EQ-5D, whereas patients with SO indicated more problems in the pain/discomfort dimension. However, none of these differences were statistically significant (Fig. 1) . Also the EuroQol VAS showed no significant difference between the group with PSE and SO. EuroQol results were converted to the EuroQol health index, which did not result in a significant difference between groups. However, in a stroke-specific QOL questionnaire, the SA-SIP-30, we found significantly higher sum scores in the group with PSE than in the group with SO (see Table 2 ), indicating a lower stroke-related QOL. In the subdivision of the SA-SIP-30 we found that patients with PSE had a higher score in the physical dimension, meaning that they reported more physical problems than patients with SO. We found no differences in the psychosocial dimension.
Also, the total HADS and subscores did not differ between groups (see Table 2 ).
Disability and neurological impairment
The Barthel index in the group with PSE showed no significant difference with the group with SO. However, the mRS was significantly higher in patients with PSE compared with patients with SO (see Table 2 ), which concurred with the significantly higher NIHSS at the time of our study in the patients with PSE (mean NIHSS 4.9 vs 1.6 in patients with SO; p b 0.01). However, when looking at the NIHSS at the time of the stroke, which we had to determine retrospectively (therefore leading to missing data on 6 patients in the group with PSE and on 5 patients in the group with SO), stroke severity in patients with PSE was not different from the severity in patients with SO (mean NIHSS 9.7 vs 6.9, p N 0.05) (see Table 1 ).
Discussion
In our case-control study, we found that patients with PSE had more cognitive problems, especially in the central information processing speed, than patients with SO. Also, the MMSE, a screening test for cognitive function, was lower in patients with PSE, indicating more cognitive problems. Furthermore, our patients with PSE also had a lower diseasespecific QOL, and they were more disabled than patients with SO.
Cognitive function in patients with PSE
In patients who have had a stroke, the effect of seizures on cognitive function is still unclear. Deterioration of cognitive function in patients with PSE may be caused by brain damage due to stroke, the effect of seizures themselves, or the side effects of AEDs. It is assumed that newer AEDs cause less cognitive side effects; however, due to methodologic issues, there remains uncertainty about the cognitive side effects of each AED [15] . In our study, 5 patients used phenytoin, which is known for its cognitive side effects [16] . This could have negatively influenced their test results. However, levetiracetam, which is assumed to have no cognitive side effects, was the most commonly used AED in our patients. This possibly leads to a dilution of the phenytoin effect on the test results. Our results provide some evidence for the double hit hypothesis of accelerated cognitive aging [17] , in which the stroke is the first hit and the PSE the second. Indeed, patients with PSE did worse on our cognitive tests compared with matched patients who have had a stroke, suggesting an additional effect of PSE or AED treatment on cognitive function.
Quality of life in patients with PSE
Our patients with PSE had a lower disease-specific QOL, they were more disabled and had more neurological impairment than patients with SO. These results are in line with previous studies. Winter et al. [4] found a lower QOL as measured with a generic QOL test (EuroQol) and lower Barthel index score, indicating more disability, in their cohort of 23 patients with PSE. However, in their study, they used nonmatched patients who have had a stroke without epilepsy as a comparison. Stroke-related characteristics, like stroke severity, influence health-related QOL, so the difference in QOL and disability score they found might be rather a reflection of stroke severity than of epilepsy. Also, Arntz et al. and Bryndziar et al. found a higher mRS, indicating more disability, in patients with PSE [18, 19] . On the other hand, the use of AED might also have influenced the QOL in patients with PSE, though others only found controversial results with positive as well as negative consequences of AED use for the QOL [20] . Thus, AED use could play a role in the lower QOL in our study, but it is not likely to be the only explanatory factor. Statistics with Mann-Whitney U test or Chi square-test, whichever was appropriate. ⁎ statistically significant difference. Fig. 1 . % of patients reporting any problems in the items of the EQ-5D. PSE = group with poststroke epilepsy; SO = group with stroke only.
Neurological deficit in patients with PSE
We found that the neurological deficit in patients with PSE was larger than in patients with SO, though the initial stroke severity was not different (NIHSS at time of stroke). This is reflected by the higher scores on the NIHSS at time of the study, the higher mRS and the higher scores in the SA-SIP-30 questionnaire (physical dimension). It seems that our patients with PSE did not recover as well as our patients with SO, whereas the absolute decrease in NIHSS scores is similar. The recovery might have been hampered by AED use, or it might reflect a disease process which also causes PSE. This suggests that PSE causing infarcts is located more strategically or have a larger or wider impact on brain recovery than those infarcts which do not cause PSE.
Strengths and limitations
Despite our interesting results, our study has some limitations. First, we performed a case-control study in which we tried to find the best match for each patient with PSE. We did find a matching patient with SO for most patients with PSE, but had to accept some differences in gender and stroke location. Second, we did not have NIHSS scores available for our patients at the time of their stroke and had to assess these scores retrospectively. In 11 patients, we had insufficient data, which makes our statement that NIHSS scores were equal at the time of stroke less valid.
However, thanks to our thorough phenotyping of our patients with PSE, we could demonstrate for the first time that cognition could be a problem in patients with PSE, and suggest that this might relate to the epilepsy itself and was not solely the consequence of stroke. Disease specific QOL is worse in patients with PSE, and disability is higher in patients with PSE, which also leads to less patients living independent.
Conclusions
We found that PSE relates to impaired cognitive functioning, a lower disease-specific quality of life and more disability and neurological impairment. These findings warrant more etiological research on the specific cognitive consequences of PSE.
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